# SRS Sequential Sindilimab in Brain Metastasis of NSLSC

> **NCT04180501** · PHASE2 · UNKNOWN · sponsor: **Xiaorong Dong** · enrollment: 25 (estimated)

## Conditions studied

- NSCLC Stage IV
- Brain Metastases
- SRS
- Sintilimab

## Interventions

- **COMBINATION_PRODUCT:** SRS sequential sintilimab

## Key facts

- **NCT ID:** NCT04180501
- **Lead sponsor:** Xiaorong Dong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11
- **Primary completion:** 2021-09
- **Final completion:** 2021-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04180501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04180501, "SRS Sequential Sindilimab in Brain Metastasis of NSLSC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04180501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*